• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Aptium Oncology Launches Myeloma Research Network as IOM Calls for Improvements in Cancer Research

Aptium Oncology Launches Myeloma Research Network as IOM Calls for Improvements in Cancer Research

May 5, 2010
CenterWatch Staff

Aptium Oncology, a consulting and management company for cancer centers, is putting together a network of investigators specifically focused on myeloma and related cancers. The Aptium Oncology Myeloma Consortium (AMyC) is modeled after Aptium’s GI Cancer Consortium, a group launched in 2008 to focus on gastrointestinal cancers.

“What we did with the GI Consortium—AGICC—was to pull together a group of investigators who are opinion leaders in GI cancer treatment and who practice at institutions that have robust GI programs already in place and access to a large number of GI cancer patients. We gathered those investigators and institutions together, and we’re supplying them with a grant, the purpose of which is to enhance their programs,” said Marti McKinley, vice president of clinical research programs for both AGICC and AMyC.

The researchers, who hail from 11 of the country’s largest cancer centers, will assist in the development and execution of phase Ib and phase II industry-sponsored trials.

Aptium hopes this initial investment will result in a long-term business strategy.

“It’s almost like another business line for the company,” McKinley said. “What we have set out to do—and what we are doing with the GI consortium—is work with pharma companies to actually write the protocols with them and our investigators and to get the studies up and running. We take care of contractual arrangements—we have master agreements in place with each of the institutions. We’ll do the data collection, provide for the data analysis and work with the companies to produce a clinical trial report and then, of course, publish.”

The launch of the AMyC coincides with an Institute of Medicine report released last week saying that the government-funded Clinical Trials Cooperative Group Program, part of the National Cancer Institute (NCI), is “approaching a state of crisis” as late-stage clinical trials are being bogged down by waste and inefficiency. The Cooperative Group Program comprises more than 3,100 institutions and 14,000 investigators and enrolls about 25,000 patients a year. Despite these resources, according to the report, 40% of late-stage cancer trials end before completion.

The report, conducted at the request of NCI director John Niederhuber, recommended that the Cooperative Group Program improve the design and conduct of cancer trials to be more efficient and provide incentives to physicians and patients to increase participation.

McKinley said problems like those cited in the report are what led to the formation of Aptium’s consortia.

“We see a big gap in the way that drugs are developed, with pharma companies kind of struggling to get trials up and running and recruited on time,” McKinley said.

AMyC will be directed by Brian Durie, M.D., the co-founder and chair of the International Myeloma Foundation. Fifteen investigators applied to be a part of the consortium, and 11 were selected based on the strength of the investigators, their associated institutions and their perceived ability to quickly move studies through the clinical trial process.

Aptium is planning for the first two myeloma trials to begin soon. The company’s GI Consortium has three trials ongoing for two different pharma companies.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing